Collegium Pharmaceutical Stock Fundamentals
| COLL Stock | USD 30.79 0.83 2.77% |
Collegium Pharmaceutical fundamentals help investors to digest information that contributes to Collegium Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Collegium Stock. The fundamental analysis module provides a way to measure Collegium Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Collegium Pharmaceutical stock.
At this time, Collegium Pharmaceutical's Income Before Tax is quite stable compared to the past year. Net Income is expected to rise to about 50.6 M this year, although the value of Other Operating Expenses will most likely fall to about 222.1 M. Collegium | Select Account or Indicator |
Collegium Pharmaceutical Company Operating Margin Analysis
Collegium Pharmaceutical's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Collegium Pharmaceutical Operating Margin | 0.35 % |
Most of Collegium Pharmaceutical's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Collegium Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Collegium Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Collegium Pharmaceutical has an Operating Margin of 0.3517%. This is 101.0% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The operating margin for all United States stocks is 106.38% lower than that of the firm.
Collegium Pharmaceutical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Collegium Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Collegium Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Collegium Pharmaceutical competition to find correlations between indicators driving Collegium Pharmaceutical's intrinsic value. More Info.Collegium Pharmaceutical is number one stock in return on equity category among its peers. It is rated second in return on asset category among its peers reporting about 0.23 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Collegium Pharmaceutical is roughly 4.43 . At this time, Collegium Pharmaceutical's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Collegium Pharmaceutical by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Collegium Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Collegium Pharmaceutical's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Collegium Pharmaceutical could also be used in its relative valuation, which is a method of valuing Collegium Pharmaceutical by comparing valuation metrics of similar companies.Collegium Pharmaceutical is currently under evaluation in operating margin category among its peers.
Collegium Pharmaceutical Current Valuation Drivers
We derive many important indicators used in calculating different scores of Collegium Pharmaceutical from analyzing Collegium Pharmaceutical's financial statements. These drivers represent accounts that assess Collegium Pharmaceutical's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Collegium Pharmaceutical's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 688.5M | 689.2M | 652.6M | 1.0B | 934.7M | 981.4M | |
| Enterprise Value | 540.1M | 781.7M | 724.9M | 1.5B | 1.3B | 1.4B |
Collegium Pharmaceutical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Collegium Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Collegium Pharmaceutical's managers, analysts, and investors.Environmental | Governance | Social |
Collegium Fundamentals
| Return On Equity | 0.43 | ||||
| Return On Asset | 0.0968 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.35 % | ||||
| Current Valuation | 1.72 B | ||||
| Shares Outstanding | 32.25 M | ||||
| Shares Owned By Insiders | 1.64 % | ||||
| Shares Owned By Institutions | 98.36 % | ||||
| Number Of Shares Shorted | 6.21 M | ||||
| Price To Earning | 28.80 X | ||||
| Price To Book | 4.12 X | ||||
| Price To Sales | 1.61 X | ||||
| Revenue | 566.77 M | ||||
| Gross Profit | 345.74 M | ||||
| EBITDA | 308.33 M | ||||
| Net Income | 48.16 M | ||||
| Cash And Equivalents | 122.72 M | ||||
| Cash Per Share | 3.60 X | ||||
| Total Debt | 674.28 M | ||||
| Debt To Equity | 3.82 % | ||||
| Current Ratio | 0.99 X | ||||
| Book Value Per Share | 7.27 X | ||||
| Cash Flow From Operations | 274.75 M | ||||
| Short Ratio | 18.07 X | ||||
| Earnings Per Share | 2.34 X | ||||
| Target Price | 42.25 | ||||
| Number Of Employees | 197 | ||||
| Beta | 0.95 | ||||
| Market Capitalization | 966.22 M | ||||
| Total Asset | 1.14 B | ||||
| Retained Earnings | (233.19 M) | ||||
| Working Capital | 79.69 M | ||||
| Current Asset | 96.88 M | ||||
| Current Liabilities | 8.43 M | ||||
| Net Asset | 1.14 B |
About Collegium Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Collegium Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Collegium Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Collegium Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -14.4 M | -13.7 M | |
| Total Revenue | 566.8 M | 595.1 M | |
| Cost Of Revenue | 240.6 M | 122.5 M | |
| Stock Based Compensation To Revenue | 0.05 | 0.05 | |
| Sales General And Administrative To Revenue | 0.27 | 0.37 | |
| Research And Ddevelopement To Revenue | 0.01 | 0.01 | |
| Revenue Per Share | 16.80 | 17.64 | |
| Ebit Per Revenue | 0.29 | 0.31 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Collegium Pharmaceutical Piotroski F Score and Collegium Pharmaceutical Altman Z Score analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.49) | Earnings Share 2.34 | Revenue Per Share 18.538 | Quarterly Revenue Growth 0.165 | Return On Assets 0.0968 |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.